Aviptadil
Early humanSynthetic VIP analogue
Research material. Not for human or animal consumption.
Research overview
Aviptadil is a synthetic form of vasoactive intestinal peptide (VIP), a 28-amino-acid neuropeptide that relaxes smooth muscle, widens blood vessels and dampens inflammation through VPAC1 and VPAC2 receptors. VIP is abundant in the lungs, which drew interest in it for pulmonary disease. Aviptadil was studied as an inhaled treatment in a small pulmonary hypertension study and as an intravenous infusion in COVID-19 respiratory failure trials, which did not lead to authorisation. In some countries it is combined with phentolamine for erectile dysfunction.
Limited, exploratory, early phase or small human studies have been identified.
Questions about Aviptadil
PRODUCT QUESTIONSWhat is Aviptadil?
Aviptadil is a 28 residue peptide identical in sequence to human vasoactive intestinal peptide, with an amidated C terminus. It belongs to the same peptide family as secretin and glucagon.
What research has been published on Aviptadil?
An exploratory study of 20 people with pulmonary arterial hypertension examined inhaled aviptadil and haemodynamic responses. During the COVID 19 pandemic, intravenous aviptadil was tested in critically ill patients with respiratory failure; results were mixed and did not lead to authorisation. Laboratory work covers VIP receptor signalling in airway and vascular tissue.
What batch documentation should accompany Aviptadil?
Aviptadil: Ask for the COA and analytical reports for the batch being quoted. For a 28 residue peptide, ask for mass spectrometry, HPLC purity with the impurity profile, peptide content, and data showing that methionine oxidation and deamidation products are controlled.
How should Aviptadil storage conditions be assessed?
Aviptadil is unstable in solution, partly because it sticks to surfaces and its methionine oxidises. Keep it lyophilised at −20°C away from light, and use low binding containers when preparing solutions.